{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T03:01:16Z","timestamp":1776049276239,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003559","name":"Ministry of National Defense","doi-asserted-by":"publisher","award":["523\/2017\/DA"],"award-info":[{"award-number":["523\/2017\/DA"]}],"id":[{"id":"10.13039\/501100003559","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.coph.2019.02.003","type":"journal-article","created":{"date-parts":[[2019,3,19]],"date-time":"2019-03-19T20:18:47Z","timestamp":1553026727000},"page":"40-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["P2X7 purinoceptor as a therapeutic target in muscular dystrophies"],"prefix":"10.1016","volume":"47","author":[{"given":"Dariusz C","family":"G\u00f3recki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2019.02.003_sbref0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","article-title":"The pathogenesis and therapy of muscular dystrophies","volume":"16","author":"Guiraud","year":"2015","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.coph.2019.02.003_sbref0010","first-page":"683","article-title":"Sarcoglycanopathies working group","volume":"27","author":"Marsolier","year":"2017","journal-title":"1st International Workshop on Clinical Trial Readiness for Sarcoglycanopathies 15-16 November 2016"},{"key":"10.1016\/j.coph.2019.02.003_bib0015","first-page":"2105","article-title":"Skeletal muscle fatigue-regulation of excitation-contraction coupling to avoid metabolic catastrophe","volume":"125","author":"Macintosh","year":"2012","journal-title":"J Cell Sci"},{"key":"10.1016\/j.coph.2019.02.003_bib0020","doi-asserted-by":"crossref","first-page":"4605","DOI":"10.1113\/jphysiol.2010.200113","article-title":"CFTR channels and adenosine triphosphate release: the impossible rendez-vous revisited in skeletal muscle","volume":"588","author":"Becq","year":"2010","journal-title":"J Physiol"},{"key":"10.1016\/j.coph.2019.02.003_bib0025","first-page":"483","article-title":"Purinergic receptors in skeletal muscles in health and in muscular dystrophy","volume":"60","author":"Krasowska","year":"2014","journal-title":"Postepy Biochem"},{"key":"10.1016\/j.coph.2019.02.003_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/wmts.96","article-title":"P2X receptor signaling in skeletal muscle health and disease","author":"Young","year":"2013","journal-title":"WIREs Membr Transp Signal"},{"key":"10.1016\/j.coph.2019.02.003_sbref0035","first-page":"1","article-title":"The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression","author":"Burnstock","year":"2017","journal-title":"Purinergic Signal"},{"key":"10.1016\/j.coph.2019.02.003_bib0040","doi-asserted-by":"crossref","first-page":"R1173","DOI":"10.1152\/ajpregu.00735.2009","article-title":"Regulatory interactions between muscle and the immune system during muscle regeneration","volume":"298","author":"Tidball","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.coph.2019.02.003_bib0045","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbamcr.2008.01.024","article-title":"Nucleotide- and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade","volume":"1783","author":"Yegutkin","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.coph.2019.02.003_sbref0050","doi-asserted-by":"crossref","first-page":"7907","DOI":"10.1074\/jbc.274.12.7907","article-title":"Ecto-ATPase activity of alpha-sarcoglycan (adhalin)","volume":"274","author":"Betto","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coph.2019.02.003_bib0055","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1042\/BJ20031644","article-title":"Characterization of the ATP-hydrolysing activity of alpha-sarcoglycan","volume":"381","author":"Sandona","year":"2004","journal-title":"Biochem J"},{"key":"10.1016\/j.coph.2019.02.003_bib0060","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1097\/00005344-199606000-00015","article-title":"ATP-stimulated release of ATP by human endothelial cells","volume":"27","author":"Bodin","year":"1996","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.coph.2019.02.003_bib0065","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/hmg\/11.3.263","article-title":"A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice","volume":"11","author":"Porter","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2019.02.003_bib0070","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0002-9440(10)62270-5","article-title":"A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice","volume":"166","author":"De Luca","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coph.2019.02.003_bib0075","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.nmd.2014.04.006","article-title":"Long-term administration of the TNF blocking drug Remicade (cV1q) to mdx mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac function","volume":"24","author":"Ermolova","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.coph.2019.02.003_bib0080","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ebiom.2015.02.014","article-title":"Functional and morphological improvement of dystrophic muscle by interleukin 6 receptor blockade","volume":"2","author":"Pelosi","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.coph.2019.02.003_bib0085","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/hmg\/ddq523","article-title":"Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype","volume":"20","author":"Villalta","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2019.02.003_bib0090","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.nmd.2006.06.011","article-title":"Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice","volume":"16","author":"Hodgetts","year":"2006","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.coph.2019.02.003_bib0095","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.4049\/jimmunol.153.10.4798","article-title":"Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy","volume":"153","author":"Gussoni","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.coph.2019.02.003_bib0100","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1096\/fj.06-7285com","article-title":"Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression","volume":"21","author":"Pescatori","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.coph.2019.02.003_bib0105","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1212\/01.wnl.0000173836.09176.c4","article-title":"Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy","volume":"65","author":"Chen","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.coph.2019.02.003_bib0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/path.2213","article-title":"T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid\/mdx mouse","volume":"213","author":"Farini","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.coph.2019.02.003_bib0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/clim.2000.4966","article-title":"Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle","volume":"98","author":"Spencer","year":"2001","journal-title":"Clin Immunol"},{"key":"10.1016\/j.coph.2019.02.003_bib0120","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.pmrj.2009.04.010","article-title":"Immune mediated mechanisms potentially regulate the disease time-course of Duchenne muscular dystrophy and provide targets for therapeutic intervention","volume":"1","author":"Evans","year":"2009","journal-title":"PM R"},{"key":"10.1016\/j.coph.2019.02.003_sbref0125","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/j.2040-4603.2018.tb00051.x","article-title":"Immunobiology of inherited muscular dystrophies","volume":"8","author":"Tidball","year":"2018","journal-title":"Compr Physiol"},{"key":"10.1016\/j.coph.2019.02.003_bib0130","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1093\/hmg\/ddy288","article-title":"Targeting RAGE as a potential therapeutic approach to Duchenne muscular dystrophy","volume":"27","author":"Sagheddu","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2019.02.003_bib0135","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12915-018-0501-z","article-title":"Downregulation of the NLRP3 inflammasome by adiponectin rescues Duchenne muscular dystrophy","volume":"16","author":"Boursereau","year":"2018","journal-title":"BMC Biol"},{"key":"10.1016\/j.coph.2019.02.003_bib0140","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1006\/mthe.2001.0496","article-title":"Immune evasion by muscle-specific gene expression in dystrophic muscle","volume":"4","author":"Hartigan-O\u2019Connor","year":"2001","journal-title":"Mol Ther"},{"key":"10.1016\/j.coph.2019.02.003_sbref0145","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne\u2019s muscular dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coph.2019.02.003_bib0150","doi-asserted-by":"crossref","first-page":"R69","DOI":"10.1093\/hmg\/ddr105","article-title":"Therapeutic approaches to muscular dystrophy","volume":"20","author":"Goyenvalle","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coph.2019.02.003_bib0155","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ana.22024","article-title":"Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy","volume":"67","author":"Malik","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.coph.2019.02.003_bib0160","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1016\/j.ajpath.2015.08.010","article-title":"Enhancement of muscle T regulatory cells and improvement of muscular dystrophic process in mdx mice by blockade of extracellular ATP\/P2X Axis","volume":"185","author":"Gazzerro","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coph.2019.02.003_bib0165","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1096\/fj.05-4022com","article-title":"Increased susceptibility to ATP via alteration of P2X receptor function in dystrophic mdx mouse muscle cells","volume":"20","author":"Yeung","year":"2006","journal-title":"FASEB J"},{"key":"10.1016\/j.coph.2019.02.003_bib0170","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/j.1582-4934.2011.01397.x","article-title":"P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: relationship to pathology and potential target for treatment","volume":"16","author":"Young","year":"2012","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.coph.2019.02.003_sbref0175","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1007\/s00018-016-2132-2","article-title":"Fast skeletal myofibers of mdx mouse, model of Duchenne muscular dystrophy, express connexin hemichannels that lead to apoptosis","volume":"13","author":"Cea","year":"2016","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.coph.2019.02.003_sbref0180","doi-asserted-by":"crossref","first-page":"C886","DOI":"10.1152\/ajpcell.1994.267.4.C886","article-title":"Responses to extracellular ATP of lymphoblastoid cell lines from Duchenne muscular dystrophy patients","volume":"267","author":"Ferrari","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.coph.2019.02.003_bib0185","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2353\/ajpath.2010.090058","article-title":"Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle","volume":"176","author":"Rawat","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coph.2019.02.003_bib0190","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jmcb\/mjx030","article-title":"Sustained activation of P2X7 induces MMP-2-evoked cleavage and functional purinoceptor inhibition","volume":"10","author":"Young","year":"2018","journal-title":"J Mol Cell Biol"},{"key":"10.1016\/j.coph.2019.02.003_bib0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081222","article-title":"Nifedipine treatment reduces resting calcium concentration, oxidative and apoptotic gene expression, and improves muscle function in dystrophic mdx mice","volume":"8","author":"Altamirano","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coph.2019.02.003_bib0200","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fchem.2018.00248","article-title":"P2RX7 purinoceptor as a therapeutic target-the second coming?","volume":"6","author":"Young","year":"2018","journal-title":"Front Chem"},{"key":"10.1016\/j.coph.2019.02.003_bib0205","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4161\/15548627.2014.994402","article-title":"A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90","volume":"11","author":"Young","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.coph.2019.02.003_bib0210","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bcp.2017.12.021","article-title":"The P2X7 receptor: a main player in inflammation","volume":"151","author":"Adinolfi","year":"2018","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.coph.2019.02.003_sbref0215","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001888","article-title":"P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of Duchenne muscular dystrophy","volume":"12","author":"Sinadinos","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.coph.2019.02.003_sbref0220","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009925","article-title":"Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy","volume":"6","author":"Villalta","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coph.2019.02.003_bib0225","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1016\/j.jbiomech.2016.09.016","article-title":"Impact of P2RX7 ablation on the morphological, mechanical and tissue properties of bones in a murine model of Duchenne muscular dystrophy","volume":"49","author":"Mohamad","year":"2016","journal-title":"J Biomech"},{"key":"10.1016\/j.coph.2019.02.003_bib0230","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.neuroscience.2004.02.008","article-title":"Altered blood-brain barrier development in dystrophic MDX mice","volume":"125","author":"Nico","year":"2004","journal-title":"Neuroscience"},{"key":"10.1016\/j.coph.2019.02.003_bib0235","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.bonr.2015.09.003","article-title":"The role of the P2X7 receptor on bone loss in a mouse model of inflammation-mediated osteoporosis","volume":"7","author":"Kvist","year":"2015","journal-title":"Bone Rep"},{"key":"10.1016\/j.coph.2019.02.003_bib0240","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.2353\/ajpath.2007.070452","article-title":"Enhanced Na+\/H+ exchange activity contributes to the pathogenesis of muscular dystrophy via involvement of P2 receptors","volume":"171","author":"Iwata","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coph.2019.02.003_bib0245","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/mus.21869","article-title":"Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-beta1 blocker","volume":"43","author":"Taniguti","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.coph.2019.02.003_sbref0250","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ajpath.2018.10.008","article-title":"The danger signal extracellular ATP is involved in the immuno-mediated damage of alpha-sarcoglycan deficient muscular dystrophy","volume":"189","author":"Gazzerro","year":"2019","journal-title":"Am J Pathol"},{"key":"10.1016\/j.coph.2019.02.003_bib0255","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1136\/annrheumdis-2011-143578","article-title":"D1520C00001 study team: clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine","volume":"71","author":"Keystone","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coph.2019.02.003_bib0260","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3899\/jrheum.110874","article-title":"Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate","volume":"39","author":"Stock","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coph.2019.02.003_bib0265","first-page":"2247","article-title":"Safety and efficacy of an oral inhibitor of the purinergic receptor P2X7 in adult patients with moderately to severely active Crohn\u2019s disease: a randomized Placebo-controlled, double-blind, phase IIa study","volume":"21","author":"Eser","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.coph.2019.02.003_bib0270","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1126\/science.1261754","article-title":"Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity","volume":"346","author":"Fowler","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.coph.2019.02.003_bib0275","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.22153","article-title":"Structural basis for subtype-specific inhibition of the P2X7 receptor","volume":"5","author":"Karasawa","year":"2016","journal-title":"eLife"},{"key":"10.1016\/j.coph.2019.02.003_sbref0280","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40478-018-0530-4","article-title":"Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism","volume":"6","author":"Al-Khalidi","year":"2018","journal-title":"Acta Neuropathol Commun"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218301401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489218301401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:50:47Z","timestamp":1761461447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489218301401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":56,"alternative-id":["S1471489218301401"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2019.02.003","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"P2X7 purinoceptor as a therapeutic target in muscular dystrophies","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2019.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}